Dr Reddy's Laboratories among four key stocks to trade Ex-dividend today
July 10, 2025, was decided as the record date for identifying the list of qualified shareholders to receive the dividends that these companies had announced.
In order for their names to appear on the list of eligible shareholders to receive the dividends, investors who wanted to receive dividends from these firms had to buy shares using the T+1 settlement method at least one day before the record date.
Dr. Reddy's Laboratories Limited—The company had recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25
LMW Limited— The company had recommended a dividend of Rs. 30 per equity share with a face value of Rs. 10 each for the fiscal year ending March 31, 2025. The same, however, is subject to shareholder approval at the subsequent Annual General Meeting.
Wheels India Limited—The Board of Wheel India had recommended a final dividend of Rs. 7.03 (70.3%) per equity share of Rs. 10/- each for the fiscal year that concluded on March 31, 2025, provided that the members of the company approve it at the subsequent AGM. If members approve the dividend, it will be paid by August 15, 2025, at the latest, as per the company. July 10, 2025, is the record date for the final dividend payment.
Diffusion Engineers Limited—The Board of Diffusion Engineers had recommended a final dividend of Rs. 1.50 (one rupee fifty paisa only) on the equity shares of the company having a face value of Rs. 10/- each for the financial year 2024-25. The same translates into a dividend of 15.00% per equity share and is subject to approval of the shareholders at the ensuing Annual General Meeting.
The dividend, if approved by the members of the Company at the ensuing Annual General Meeting ('AGM'), will be paid within 30 days from the date of AGM, as per the company
Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
36 minutes ago
- Time of India
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 이 게임은 대부분의 TV 프로그램보다 더 재미있어요 – 게다가 무료예요. Raid: Shadow Legends 플레이하기 Undo The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. Live Events India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores.
Indian Express
41 minutes ago
- Indian Express
Rs 55,000 discount on Samsung Galaxy S24 Ultra: Here's why its a steal deal
Prime Day is here, and so are lucrative deals on electronics and smartphones. One of the most sold Samsung flagship devices, the Galaxy S24 Ultra, is one of the prime attractions of the sales season. The top-of-the-line smartphone is coming with a discount of about Rs 55,000. Launched at Rs 1,29,999, Amazon is now offering the premium device at Rs 74,999 along with a slew of offers. If you are looking to buy a new phone, Samsung's S24 Ultra can be the ideal upgrade. The 12 GB RAM + 256 GB storage version is now selling at almost half the price of the MRP at launch. In addition to the discounted price, Prime members can also get 5 per cent cash back with the Amazon Pay ICICI Bank credit card. Note: The Prime Day sale will end on July 14, but the discount on the Galaxy S24 Ultra may end earlier than expected. The Samsung Galaxy S24 Ultra was launched in January 2024. The premium flagship is ideal for those looking to own a smartphone that will easily for more than half a decade. It features a flat 2K resolution display, an ever-so-slightly curved frame, and an ultrasonic fingerprint sensor that is among the best in the industry. Another reason to buy the S24 Ultra is the S Pen, which comes with Bluetooth connectivity for additional features. The Samsung S24 series is the first to introduce AI-powered smartphones with integrated Galaxy AI. Samsung introduced some cool features, such as Circle to Search, image editing, and live translations, which have become essential for most Samsung users. The S24 Ultra is powered by a Qualcomm Snapdragon 8 Gen 3 processor and is backed by 12 GB of RAM, providing the user with a smoother experience. The Samsung Galaxy S24 Ultra is the ultimate device for phone photography with its quad camera setup. Cameras are as follows: the main camera is a 200 MP lens, the 50 MP 5x periscope lens, the 12 MP ultrawide lens, and the 10 MP 3x telephoto lens. It also features a 6.8-inch Dynamic AMOLED 2K display with a 120 Hz refresh rate. The S24 Ultra also offers a long-lasting battery of 5,000 mAh. Also, Samsung promises to provide seven years of OS updates, ensuring longevity for its devices.
News18
an hour ago
- News18
BEML Stock Split 2025: Board to Consider Share Sub-Division On July 21
BEML Ltd, formerly Bharat Earth Movers Limited, is an India PSU that engages in manufacturing of a variety of heavy equipment, including products for defense, mining, construction and rail/metro sectors. It was incorporated in 1964. BEML Ltd has a market cap of Rs 18,431 crore and is part of BSE 500 as of July 11. BEML Ltd's shares ended 3.85 per cent lower at Rs 4425.80 apiece on Friday. The day's opening and close stood at Rs 4603.20 apiece each. What Is A Stock Split? A stock split is when a company divides its existing shares into multiple new shares to make them more affordable for investors — without changing the overall value of the company. Example: Stock Split from Rs 10 to Rs 2 Face Value Let's say you own 100 shares of a company: Note that this is just an example to clarify the concept. BEML Ltd board may announce any ratio of stock split. BEML Share Price History Over the past five years, from mid-2020 to July 2025, BEML's share price has surged by approximately 720%, showcasing robust investor confidence. In the short term, BEML's share price showed notable movements. In the last week of May 2025, the stock rose by approximately 7.95%, and over the past month, it gained 24.82%. Over three months, it surged by 49.59%, indicating strong bullish momentum. However, on a year-to-date basis in 2025, the stock was up by 9.73%. Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.
